The Nigerian Investor
← All researchMeCure Industries Plc (MECURE) · Pharmaceuticals · 9M 2026

MeCure 9M 2026: Operations Fire, but the Bank Takes Half

The verdict

MeCure is the most improved operator in listed pharma. Revenue rose 17% to N70.24bn, marketing spend halved, and EBIT margin widened to about 24.9%. But finance costs of N8.84bn absorbed about 51% of EBIT, so interest cover is only about 1.98x. Net debt of about N55.2bn is roughly 2.2x equity, and at N56.20 the stock trades near 28x trailing earnings and 9x book, with a free float of only 13.89%. Execution is strong, but the balance sheet and price leave no margin of safety. The September rate cut is the key upside catalyst.

Key numbers (N'000)

Item

9M 2026

9M 2025

Change

Revenue

70,237,937

60,008,738

+17.0%

Gross profit

24,128,082

20,408,844

+18.2%

Gross margin

34.4%

34.0%

+0.4ppt

Marketing

1,299,457

2,644,770

−50.9%

Admin

5,784,148

4,888,051

+18.3%

EBIT

17,485,615

13,017,876

+34.3%

Finance cost

8,840,779

6,647,655

+33.0%

PBT

8,644,836

6,370,221

+35.7%

PAT

6,051,385

4,459,155

+35.7%

EPS

N1.51

N1.11

+36%

Q3 revenue / PAT

25,392,860 / 2,568,955

22,746,684 / 1,725,758

+11.6% / +48.9%

Total borrowings

59,506,654

55,332,956 (Dec 25)

+7.5%

Equity

24,585,984

19,821,600 (Dec 25)

+24.0%

Source: MeCure 9M 2026 unaudited filing (NGX). Percentages are TNI Research calculations.

What drove the results

Revenue mix: acute care N40.24bn (+19.6%); OTC N14.61bn (+28.3%); narcotics N2.83bn (+169%); new contract manufacturing (N935.5m) and promotional sales (N316.0m). Multivitamins fell 32% to N5.75bn, the one weak line to monitor.

Costs and margins: direct materials rose only 7.4% against 17% revenue growth, and customs duty in cost of sales fell from N695.7m to N169.9m, consistent with the raw-material duty waiver. Higher depreciation (N4.27bn in cost of sales) offset part of these savings, so gross margin barely moved. The operating leap came from marketing spend falling by N1.35bn; investors should ask whether that cut is sustainable or deferred.

Q3 momentum: revenue growth slowed to 11.6%, but Q3 PAT still rose 49% and Q3 interest cover improved to about 2.3x.

Forensic flags

  1. Leverage and refinancing. Commercial paper fell from N26.03bn to N14.17bn while term loans rose from N14.69bn to N26.68bn. That lengthens maturities but does not reduce debt. Bank charges nearly tripled to N732.5m.

  2. Debt classification inconsistency. The balance sheet shows the working-capital and term loans as non-current, but Note 19 lists all borrowings under "Current". If the note is right, liquidity is far weaker than the balance sheet suggests.

  3. Tax not paid; possible Development Levy under-provision. No tax was paid in 9M 2026 and the current tax liability almost doubled to N5.21bn, which flatters operating cash flow. The tax charge is exactly 30.0% of PBT, so it is unclear whether the 4% Development Levy is provided.

  4. Related-party receivable. N6.40bn is due from MeCure Healthcare Ltd for a cancer centre investment, to be repaid from 30% of radiotherapy revenue once treatment begins. That is an open-ended, owner-related loan with no fixed repayment date.

  5. Capex payoff. Capex of N16.69bn (about 24% of revenue) was mostly work in progress: Project Ignite (N12.94bn) and oncology (N1.96bn). Free cash flow was about −N6.3bn.

  6. Disclosure quality is the weakest in this batch. The cash flow is labelled "30 June 2025"; the tax note says "At 30 June"; the interest-rate note says "The Company had no borrowings" against N59.5bn of debt; the revenue policy refers to "diagnostic" services. None of these changes the numbers, but together they suggest weak review controls over the filing.

  7. Concentrated ownership. The Udani family holds about 85%, and the free float is 13.89% (compliant for the Growth Board).

Valuation (TNI Research calculations)

  • N56.20 × 4.0bn shares: market cap about N224.8bn.

  • TTM PAT about N8.06bn; EPS about N2.01; P/E about 27.9x.

  • P/B about 9.1x; EV about N280bn.

  • FY2025 dividend N0.32, a yield of about 0.6%. No interim dividend.

  • Low liquidity means the quoted price may not be a reliable valuation anchor.

What to watch

  • Finance costs in Q4 after the rate cut to 23%.

  • The audited classification of borrowings.

  • Tax and Development Levy true-up at FY.

  • Commissioning date and revenue from Project Ignite.

  • Repayment progress on the MeCure Healthcare receivable.

  • Whether multivitamin sales stabilise.

Sources

Source: MeCure 9M 2026 unaudited NGX filing. This is analysis for education, not investment advice.

TNI Research publishes independent analysis for education. It is not investment advice. Do your own research or consult a licensed adviser before investing.